Pharmacological Inhibitors Of Mnk For The Treatment Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$505,894.00
Summary
Cancer is a leading cause of death worldwide. In 2010 an estimated 43,000 Australians died from cancer and 114,000 new cases were diagnosed. New treatments are urgently needed. Protein kinases Mnks promote human tumourogenesis, but they are dispensable for normal tissue development. Inhibition of Mnks’ activity therefore presents an excellent strategy for effective and nontoxic cancer therapy. This project aims to develop Mnk inhibitor drug candidates for potential clinic application.
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.